Cotinga Pharmaceuticals

Cotinga Pharmaceuticals, Inc.Cotinga Pharmaceuticals is a biopharmaceutical company developing therapies for cancer and other unmet medical needs. The company's lead compound is COTI-2, a clinical-stage oral small molecule targeting the p53 tumor suppressor gene. It is also developing COTI-219, an oral small molecule compound targeting mutant forms of KRAS without inhibiting normal KRAS function.